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ABSTRACT 
Backgrounds 
Transcatheter aortic valve implantation (TAVI) has become the treatment of choice in 
patients with severe symptomatic aortic stenosis (AS) considered inoperable or at 
high surgical risk. More recently, TAVI has been performed also to lower risk patients 
based on the Heart Team decision. Few studies have studied interaction between 
surgical risk categories and outcomes. 
Aim of the study 
To analyze safety and efficacy (VARC-2 defined) TAVI treated patients as function of 
different preoperative risk. To assess independent predictors of death.  
Methods 
Four-hundred-eighty-two patients who underwent TAVI in our center between 2007 
and 2017 were included in the study. According to Society of Thoracic Surgeons (STS) 
score and to other parameters, all the patients were retrospectively stratified into 4 
groups: prohibitive (contraindications to aortic valve replacement, n = 124), high (STS 
> 8, n = 131), intermediate (4 ≤ STS ≤ 8, n = 112) and low (STS < 4, n = 115) risk. Early, 
1-year and long-term outcomes have been evaluated in those 4 groups according the 
VARC 2 criteria.  
Results 
The TAVI procedure resulted to be safe because of low mortality rate throughout all 
risk groups. The lowest 30-days mortality rate was observed in low and prohibitive-
risk patients (p=0.048). In the low risk group, in-hospital mortality was 0%. The results 
were similar at 1-year of follow-up, with a mortality rate of 6% and 7% in low- and 
prohibitive-risk patients vs 21% and 19% in intermediate- and high-risk groups, 
(p<0.008). At 5-year of follow-up the mortality rate was 52% and it appeared to be 
lower only in low-risk patients at long-term follow-up. Independent predictors of 
mortality were pre-procedural congestive heart failure (CHF), neoplastic disease, pre-
procedural-creatinine, post-procedural major or life threatening bleeding and post-
procedural acute kidney injury (AKI). Implanted prosthesis performed well with stable 
hemodynamic results over time and rare dysfunction (2.1%). 
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Conclusions 
In our study population, TAVI was safe and effective, with low rates of mortality and 
adverse events regardless of the surgical risk. At longer follow-up mortality rate was 
significantly lower in low-risk patients. Pre-procedural CHF, neoplastic diseases, pre-
procedural creatinine, post-procedural severe bleedings and post-procedural AKI 
were independent predictors of mortality. Transcatheter heart valves (THV) 
performance after the procedure was excellent and stable over time with low rate of 
late prosthesis dysfunction. Further studies should be addressed to confirm the 
promising long-term results among low-risk patients and the long-term durability of 
THV. 
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INTRODUCTION 
 
AORTIC VALVE STENOSIS 
Aortic valve Stenosis (AS) is usually caused by cups calcifications without commissural fusion. 
Consequently, valvular motion and effective area decrease and leads to blood flow 
obstruction, trans-valvular pressure gradient and left ventricular (LV) hypertrophy. The 
evolution of AS is slow, but when symptoms appear the progression is rapid towards death 
if left untreated (1,2). AS occurrence increases with age; and 2% of the overall population is 
affected after 65 years old. Moreover, one third of them shows echocardiographic signs of 
leaflet calcifications (3,4). AS is the most common primary valve disease leading to surgery 
or catheter intervention in Europe and North America, with a growing prevalence due to the 
population ageing (5-7). 
 
Natural History 
As reported by Ross and Braunwald (1), patient outcome is similar to overall population until 
symptoms occur. Clinical manifestations generally develop when the aortic valve area (AVA) 
decreases to less than 1 cm2 and are associated with a severe worsening of survival (Figure 
1) 
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Figuere 1. Natural history of aortic stenosis without treatment (1) 
 
The three principal symptoms of AS are angina, syncope, and dyspnea (or congestive heart 
failure (CHF)). (8-11) 
Angina is usually the earliest symptom and is associated to a mean survival of 4 to 5 years. 
Angina is present in around 50-70% of the patients with AS. Because of LV hypertrophy and 
end-diastolic pressure rise, myocardial perfusion decreases, especially at the level of the sub-
endocardium, and this discrepancy causes angina. 
When the patient suffers for syncope, survival is typically less than 3 years. Syncope is due 
to the reduced blood flow through the stenotic valve that causes decreased cerebral 
perfusion. Furthermore, peripheral vasodilatation during exercise may worsen this condition 
since cardiac output cannot be modified.  
Patients with dyspnea and CHF, in keeping with their associated left ventricular dysfunction, 
have a mean survival of 1 to 2 years. CHF is the presenting symptom in nearly one third of 
the patients. Dyspnea is the consequence of the reduced capacity of the heart to increase 
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the stroke volume in response to an increased metabolic demand. It can be also a 
consequence of the diastolic dysfunction (12). 
 
Stages of AS 
Medical and interventional approaches to the management of patients with AS mainly 
depend on the disease’s cause and staging. The classification of AS stages (13) is reported in 
Table 1 according to 2014 American College of Cardiology/American Heart Association 
guidelines (ACC/AHA). The stages of AS range from patients at risk of AS (stage A) or with 
progressive hemodynamic obstruction (stage B) to severe asymptomatic (stage C) and 
symptomatic AS (stage D). Each of these stages considers valve anatomy, valve 
hemodynamics, the consequences of valve obstruction on the left ventricle, as well as by 
patient symptoms. 
Hemodynamic AS severity is best characterized by the transaortic maximum velocity (or 
mean pressure gradient) when the transaortic volume flow rate is normal. However, some 
patients have low transaortic volume flow due to LV systolic dysfunction with reduced stroke 
volume. This low-flow AS subgroups requires a distinct approach compared to the majority 
of AS with high gradient and normal flow (14). 
The definition of severe AS is based on natural history studies of medically treated patients, 
in which prognosis is poor when peak aortic valve velocity is >4.0 m/sec, or mean aortic valve 
gradient is >40 mmHg.  
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Table 1. Stages of AS (Nishimura, RA et al. 2014 AHA/ACC Valvular Heart Disease Guideline) 
Stage  
 
Definition  
 
Valve Anatomy  
 
Valve 
Hemodynamics  
Hemodynamic 
Consequences 
Symptom
s 
A At risk of AS  
 
. Bicuspid aortic valve 
(or other congenital 
valve anomaly) 
. Aortic valve sclerosis 
Aortic Vmax <2 m/s None None 
B Progressive 
AS 
.Mild-to-moderate 
leaflet calcification 
with some reduction 
in systolic motion 
.Rheumatic valve 
changes with 
commissural fusion 
. Mild AS: Aortic Vmax 
2.0–2.9 m/s or mean ΔP 
<20 mm Hg 
. Moderate AS: 
Aortic Vmax 3.0–3.9 m/s 
or 
. Early LV diastolic 
dysfunction may 
be present  
. Normal LVEF 
None 
C: Asymptomatic severe AS 
C1 Asymptomati
c severe AS 
Severe leaflet 
calcification or 
congenital stenosis 
with severely reduced 
leaflet opening 
. Aortic Vmax >4 m/s or 
mean ΔP ≥40 mm Hg 
. AVA typically is ≤1.0 
cm2 (or AVAi 
<0.6cm2/m2) 
. Very severe AS is an 
aortic Vmax ≥5 m/s or 
mean ΔP ≥60 mm Hg 
. LV diastolic 
dysfunction 
. Mild LV 
hypertrophy 
. Normal LVEF 
None: 
Exercise 
testing is 
reasonable 
to confirm 
symptom 
status 
C2 Asymptomati
c severe AS 
with LV 
Dysfunction 
Severe leaflet 
calcification or 
congenital stenosis 
with severely reduced 
leaflet opening 
. Aortic Vmax ≥4 m/s or 
mean ΔP ≥40 mm Hg 
. AVA typically ≤1.0 cm2 
(or AVAi <0.6 cm2/m2) 
LVEF <50% None 
D: Symptomatic severe AS 
D1 Symptomatic 
severe high-
gradient AS 
Severe leaflet 
calcification or 
congenital stenosis 
with severely reduced 
leaflet opening 
. Aortic Vmax ≥4 m/s or 
mean ΔP ≥40 mm Hg 
. AVA typically <1.0 cm2 
(or AVAi <0.6 
cm2/m2) but may be 
larger with mixed 
AS/AR 
. LV diastolic 
dysfunction 
. LV hypertrophy 
. Pulmonary 
hypertension may 
be present 
.Exertional: 
dyspnea or 
decreasedex
ercise 
tolerance , 
or angina 
or syncope  
D2 Symptomatic 
severe low-
flow/low-
gradient AS 
with reduced  
LVEF 
Severe leaflet 
calcification with 
severely reduced 
leaflet motion 
. Aortic Vmax ≥4 m/s or 
mean ΔP ≥40 mm Hg 
. AVA typically <1.0 cm2 
(or AVAi <0.6 
cm2/m2) but may be 
larger with mixed AS/AR 
. LV diastolic 
dysfunction 
. LV hypertrophy 
. LVEF <50% 
 
. HF 
. Angina 
. Syncope or 
presyncope 
D3 Symptomatic 
severe low-
gradient AS 
with normal 
LVEF or 
paradoxical 
low-flow 
severe AS 
Severe leaflet 
calcification with 
severely reduced 
leaflet motion 
. AVA <1.0 cm2 with 
aortic Vmax <4 m/s or 
mean ΔP <40 mm Hg 
. Indexed AVA <0.6 
cm2/m2  
. Stroke volume index 
<35 mL/m2 
. Measured when patient 
is normotensive (systolic 
BP <140 mmHg) 
. Increased LV . HF 
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In case of low flow, AS may be severe with lower valve velocities and gradients, and AVA 
should be calculated. The prognosis of patients with AS is poorer when AVA is <1.0 cm2. At 
normal flow rates, AVA <0.8 cm2 generally correlates with a mean gradient >40 mmHg. 
However, symptomatic patients with calcification and AVA between 0.8 cm2 and 1.0 cm2 
should be closely evaluated to determine whether they would benefit from intervention 
(15). 
Meticulous attention to detail is mandatory when assessing aortic valve hemodynamics, 
either with Doppler echocardiography or cardiac catheterization, and the inherent variability 
of the measurements and calculations should always be considered in clinical-decision 
making. 
 
Management 
In the past, medical therapy with or without Balloon Aortic Valvuloplasty (BAV) was the only 
treatment options for inoperable patients with an average survival of 2–3 years after the 
symptoms onset (16). Over the last decade, transcatheter aortic valve implantation (TAVI) 
become the treatment of choice for inoperable patients and the preferred alternative for 
high-risk patients with severe AS.  
From Cribier’s first implantation in 2002 (17), more then 100 000 TAVI procedures have been 
performed worldwide. Nevertheless, surgical aortic valve replacement (SAVR), first reported 
in 1960 by Harken, remains the gold standard for patients at low operative risk because of 
excellent long-term outcomes and low perioperative risk. (18-20).  
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The technical advances in new transcatheter heart valves (THV) significantly improved TAVI 
safety and efficacy. The excellent TAVI results observed in recently published randomized 
controlled trials and multiple international prospective registries (21-24) have broadened 
the indications for TAVI to intermediate-risk patients as an alternative (class I, LoE B) to SAVR 
(19). This suggest that TAVI might become a valuable treatment option also for a large 
number of lower (intermediate- to low-) risk patients, representing over 80% of the subjects 
currently undergoing SAVR (25). 
In clinical practice and in randomized trials, the risk scores used to judge patient’s indication 
to TAVI have been inherited from surgery. The Society of Thoracic Surgeons predicted risk 
for mortality (STS) (26) and the logistic European System for Cardiac Operative Risk 
Evaluation (EuroSCORE) I and II (27, 28) are the most widely used scores in North America 
and Europe, respectively. Patients are usually considered at high-risk when STS score >8 or 
logistic EuroSCORE >20, at intermediate-risk when STS score is 4–8% and logistic EuroSCORE 
is 10–20, at low-risk when STS score is <4 and logistic EuroSCORE is <10. However, while 
these risk models correctly predicted SAVR outcomes (29, 30), they significantly 
overestimated TAVI mortality. The difference between predicted and observed mortality of 
surgical scores applied to TAVI was related to many confounders, including the fact that 
general anesthesia was often not needed in TAVI, and as a consequence most variables 
present in the surgical scores had a lesser influence on TAVI outcomes. Of note, several new 
TAVI risk models (31-36) had been developed, but none was routinely used nor is included 
in ongoing trials, mostly because of their complexity, poor accuracy and entry bias in regard 
to patient inclusion, that preclude broad generalization (35). Accordingly, guidelines 
acknowledge the imperfect nature of surgical risk scores and recommend that the decision 
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to perform TAVI should be made on the basis of multidisciplinary Heart Team evaluation 
(13,19). In other words, risk scores should never be a substitute for clinical judgment and the 
participation of patients and their families in to the decision. It is well documented that age 
remains one the most important reasons for surgical refusal (37), and referral to TAVI. To 
this regard, in the STS registry, SAVR patients had a mean age of 67 years and a mean STS of 
1.8% (only 6.2% patients had an STS >8%), and there was a clear correlation between STS 
value and age. On the other hand, the common thread across TAVI trials and registries 
remained the older age, regardless of risk score. Indeed, despite the absence of an absolute 
age cut-off in the inclusion criteria for most studies, TAVI patients in all major recent and 
ongoing trials are still predominantly octogenarians. This implies that ‘lower-risk’ does not 
necessarily mean ‘younger’. The relative lack of major comorbidities illustrates the common 
entity of entry bias in previous and ongoing trials comparing SAVR with TAVI, in which 
patients had to be considered eligible for both procedures in order to be included (for 
instance, in the PARTNER trial, less than one-third of the screened patients were eventually 
enrolled) (38). This is illustrated by the demographics of patients in clinical practice at large, 
in which the indication for TAVI is not simply based on surgical scores, as shown by the fact 
that almost 2/3 of patients included in contemporary European registries are at intermediate 
and even low surgical risk. Accordingly, in the STS/ACC Transcatheter Valve Therapy Registry 
TAVI patients have a mean STS score of 6.7%, and almost 70% of them are ≥ 80 years of age 
(39). 
The recommendations for choice of intervention for AS apply to both surgical AVR and TAVI. 
The decision should be based on a patient’s individual risk–benefit analysis including cardiac 
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and extracardiac characteristics, risk of surgery assessed by the Heart Team in addition to 
scores, and TAVI feasibility according to local experience and outcome. 
Data on TAVI are still very limited for patients <75 years of age and for surgical low-risk 
patients, for whom SAVR remains the reference method. It has to be emphasized that 
younger patients presented more bicuspid valves that worsen TAVI results and were usually 
excluded from trials. In addition, THV durability is still lacking. 
In elderly patients at increased surgical risk, available mortality data from trials and registries 
showed TAVI was superior to medical therapy in extreme-risk patients (40), non-inferior or 
superior to surgery in high-risk patients (41-44), and non-inferior to surgery and even 
superior when transfemoral access is possible in intermediate-risk patients (25,45-48). In the 
two large studies on intermediate risk, the mean age of patients were 82 and 80 years 
(46,48), the mean STS scores were 5.8% and 4.5%,(48) and several cases were considered 
frail. Thus, results are valid only for comparable patient groups. Overall, rates of vascular 
complications, pacemaker implantation and paravalvular regurgitation were significantly 
higher for TAVI and depended on the device (47-48). On the other hand, severe bleeding, 
acute kidney injury (AKI) and new-onset atrial fibrillation were significantly more frequent 
with surgery, whereas no differences were observed in cerebrovascular events.(47-48) The 
favorable results of TAVI had been reproduced in multiple large-scale, nationwide registries 
supporting the generalizability of outcomes observed in randomized controlled trials. This 
favors the use of TAVI over surgery in elderly patients at increased surgical risk.  
However, overall, Heart Team should make the final decision between SAVR and TAVI 
(including the choice of access route) after careful individual evaluation (19,49). 
The 2017 ACC/AHA guidelines flow chartis reported figure 2 (49). 
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Figure 2. Choice of intervention in severe AS symptomatic patients according to ACC/AHA 
2017 guideline. 
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AIM OF THE STUDY 
 
General assessment: 
First, to analyze early, 1-year and long-term outcomes of TAVI procedure in a single 
monocentric series. 
Second, to compare the outcomes of different surgical risk classes. 
Third, to assess the independent predictors of mortality. 
Fourth, to observed durability of prosthesis with time and type of dysfunction. 
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METHODS 
 
Study population 
Between Jane 2007 and February 2017, all patients affected by severe symptomatic AS or 
aortic bio-prosthesis dysfunction treated with TAVI at our Institution were collected in a 
prospective monocentric registry named PUREVALVE (Padua University Revalving 
Experience).) 
All patients underwent complete screening in order to evaluate the eligibility to TAVI and to 
choose the most appropriate vascular access and device. Blood tests, chest radiography, 
electrocardiogram, coronary angiography, multislice computed tomography (CT) scan of 
aortic root, ascending and abdominal aorta, and iliac-femoral axis, doppler ultrasound 
evaluation of carotid and vertebral arteries and pulmonary function investigation were 
performed. 
Heart Team, composed by a clinical and interventional cardiologist, a cardiac surgeon and 
an anesthetist, performed the final choice on the best treatment strategy. Furthermore, the 
patients and their families were informed for the final decision on the best treatment option. 
Patients without clinical and echocardiographic 30-day follow-up were excluded by the 
analysis, while patients died during the procedure or hospitalization were considered. 
The study population was retrospectively divided in four risk groups (low, intermediate, high 
and prohibitive) according to STS score and to other main features. Table 2 reported a 
combination of STS risk, frailty, major organ system dysfunction, and procedure-specific 
impediments for better risk assessment as reported in 2014 and 2017 AHA/ACC guidelines 
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(13,49). The prohibitive risk class included patients with almost one of these characteristics: 
1-year mortality risk higher than 50%, specific contraindications of surgical intervention or 
more than three organ system disorders (28). The low-risk class included patients with a STS 
score inferior to 4%, the patients with intermediate risk class had a STS score between 4-8% 
and the high-risk group included patients with a STS score of more than 8%. 
 
Table 2. Risk classes stratification according AHA/ACC 2014/2017 guideline. 
 
The assessment of the patient’s frailty evaluating independence in feeding, bathing, 
dressing, transferring, toileting, and urinary continence and independence in ambulation 
was used. 
Major organ system compromise included:  
- Cardiac: severe LV systolic or diastolic dysfunction or right ventricular (RV) 
dysfunction. 
- Chronic Kidney Disease stage 3 or worse 
- Pulmonary dysfunction with FEV1 <50% or DLCO2 <50% of predicted 
- Central Neurologic System dysfunction: dementia, Alzheimer’s disease, Parkinson’s 
disease, stroke with persistent physical limitation 
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- Gastro-intestinal dysfunction: Crohn’s disease, ulcerative colitis, nutritional 
impairment, or serum albumin <3.0 
- Cancer: active malignancy 
- Liver: any history of cirrhosis, variceal bleeding, or elevated INR in the absence of 
anticoagulant therapy. 
The procedure’s specific impediments were tracheostomy, heavily calcified ascending aorta, 
chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation 
damage. Table 3 were reported similar characteristics to evaluate in the choice of procedure, 
in according to 2017 ECC/EACTS guidelines (19) 
Table 3. Aspects to be considered by the Heart Team for the decision between SAVR and 
TAVI in patients at increased surgical risk 
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TAVI procedure 
The procedure was performed in a standard catheterization laboratory. Different 
approaches were used on the basis of the patients’s characteristics. Retrograde transfemoral 
access (TF) usually represented the first choice because less invasive. Transapical approach 
(TA) was usually performed under general anaesthesia and endotracheal intubation. An 
anterolateral minithoracotomy (usually fifth or sixth intercostal space) was performed. Two 
circular purse-string sutures were placed on the cardiac apex. The procedure started with an 
apical puncture. At the end of procedure, the apical puncture site could be safely secured by 
tying the purse-string sutures (50). 
Figure 3. Transfemoral (TF)and transapical (TA) approches 
For both approaches, a supra-aortic angiogram was performed to evaluate the presence and 
degree of aortic regurgitation. A 5-F sheath was placed in the right radial artery and a pigtail 
advanced (51) in the ascending aorta for hemodynamic monitoring and landmark aortic 
angiography. Transvenous temporary pacing was placed in the RV. For the TF retrograde 
approach, the native aortic valve was crossed with a straight 0.035-inch guide wire using an 
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Amplatz Left-2 coronary catheter advanced to the ascending aorta. The transvalvular 
gradient was measured and AVA calculated. BAV could be performed before valve 
implantation. The valve crimped into his catheter, was introduced on the same guide-wire 
by retrograde approach until the native aortic valve. The supra-aortic angiogram and native 
valve calcifications were used as anatomical landmarks for valve placement. Hemodynamic 
improvement was measured immediately afterwards, and a supra-aortic angiogram was 
performed in absence of renal insufficiency to assess the presence, location, and degree of 
aortic regurgitation and the patency of coronary arteries, as well as to rule out 
complications, such as aortic dissection. 
Heparin at a dose of 100 IU/kg body weight was administered to yield an activated clotting 
time of 250-300 seconds throughout the procedure. After the procedure, heparin was 
neutralized by protamine. Patients were pre-medicated with aspirin and clopidogrel. 
TAVI prosthesis  
The ideal aortic valve prosthesis should be durable, with optimal hemodynamic performance 
and able to reduce the current major complications of TAVI procedure, in particular vascular 
complications (not infrequent with the transfemoral access route), paravalvular leaks, stroke 
and atrioventricular block requiring a permanent pacemaker. Indeed, TAVI registries and 
trials showed that major vascular complications are strong predictors of morbidity and early-
mortality after TAVI. In addition, moderate and severe paravalvular leak has been associated 
with increased morbidity and mortality (52-54). Even if inconsistency is present in literature 
regarding the impact of pacemaker implantation on subsequent outcomes, also this 
complications seems to have an impact on subsequent outcomes after TAVI (55,56). 
In our patients, different devices were used (old and new-generation of valves): 
P a g i n a  | 18 
 
Edwards Lifesciences Sapien, Sapien XT and Sapien 3 THV 
The family of Edwards Sapien valve are the balloon expandable prosthesis whose leaflets are 
made of bovine pericardium mounted on a chrome-cobalt stent. The SAPIEN 3™ (S3) 
(Edwards Lifesciences, Irvine, CA, USA) is the last of Edwards family’s trans-catheter heart 
valves (THV) (Figura 4A). This device incorporates a number of new and enhanced features 
intended to reduce the risk of vascular injury and paravalvular regurgitation, and to facilitate 
rapid and accurate positioning and implantation. The SAPIEN 3 valve incorporates a cobalt 
chromium stent, bovine pericardial leaflets, and both an inner and new outer polyethylene 
terephthalate (PET) sealing cuff. The delivery system (Commander; Edwards Lifesciences, 
Irvine, CA, USA) incorporates an active three-dimensional coaxial positioning (Figura 4B) 
(53). 
 
Figure 4. The SAPIEN 3 valve; B: delivery system 
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The 20-23 and 26 mm S3 THV are compatible with a 14 Fr expandable sheath (eSheath; 
Edwards Lifesciences), while the 29 mm S3 is compatible with a 16Fr expandable sheath. The 
low diameter of the sheath reduces the stress on the access vessel by transiently expanding 
as the crimped THV passes through the sheath and then recoiling to a lower profile (Figure 
5). This may reduce the potential for arterial injury during introduction, and may extend the 
eligibility to TAVI for some patients previously considered unsuitable for the femoral 
approach due to small vessels. 
 
Figue 5. Edwards Sapien prosthesis family. 
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The external “skirt” (outer PET sealing) in the lower portion of the valve and a more accurate 
positioning of the valve due to the renovated delivery system should ensure a good sealing, 
thus preventing the occurrence of paravalvular leaks. The increased length of the S3 (20 mm 
compared to 17 mm of SAPIEN XT) will augment the need of permanent pacemaker due to 
an increased area of contact with the interventricular septum. Theoretically, a decreased 
need for oversizing due to the presence of the sealing cuff and a more accurate positioning 
with a more predictable final valve implantation depth could reduce this risk. 
The data on S3 confirmed the advantage of the this valve compared with previous Edwards 
valves (SAPIEN and SAPIEN XT) in terms of prevention of vascular complications and of 
moderate-severe paravalvular leaks, but showed an increase in the need of a permanent 
pacemaker post-TAVI (57). Data on an increased need of permanent pacemakers are not 
conclusive. In fact, a study conducted in patients treated in Padua with S3 showed that a low 
final valve implantation depth is the strongest predictor of subsequent AV conduction 
defects, rather than the valve itself (57, 58).  
 
CoreValve Family 
The Medtronic CoreValve (CV), with leaflets made from porcine pericardium sutured into a 
self-expanding nitinol frame, was the first commercially available self-expanding TAVI 
system. The US Pivotal Trial showed excellent long-term outcomes after CV implantation in 
patients classified as high-risk for surgical aortic valve replacement (59). Despite the 
generally low TAVI complication rates for such high-risk patient collective, several important 
and prognosis relevant issues including paravalvular leaks (60), access site bleeding (61) or 
valve dislocation during deployment limited the procedural success of first generation 
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prosthesis. To tackle these issues, the Evolut R (EVR) with the EnVeo R delivery catheter was 
introduced in 2014. This second generation prosthesis allows repositioning after 
implantation, has a lower delivery profile and has an extended sealing skirt to reduce the 
incidence of paravalvular leaks (Figure 6) 
 
Figure 6. Corevalve prosthesis and size. 
Compared to the traditional Medtronic CoreValve  prosthesis (left side), new features of the 
Medtronic Evolut R™ (right side) include a new design of the nitinol frame with a lower 
height and an extended sealing skirt. 
 
Symetis Acurate Neo Aortic Valve 
The ACURATE neo Aortic Valve (Symetis, Lausanne, Switzerland) (Figure 7) with 
Transfemoral and Transapical Delivery Systems, is a self-expanding, supra-annular valve, 
offering an intuitive procedure, predictable release, stable positioning, and had 
demonstrated excellent clinical outcomes. 
The most important difference to other self-expanding platforms was the top-down 
deployment with minimal protrusion of the stent towards the left ventricular outflow tract. 
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In addition, the supra-annularly placed porcine leaflets provide very low gradients and the 
pericardial skirt acted very effectively to seal against paravalvular leaks. 
The TAVI TF 1000 Registry (62) (Symetis ACURATE neo™ Valve Implantation using 
TransFemoral Access) was a post-market registry, including 1000 patients trated betwwen  
October 2014 and  April 2016. The results confirmed long-term safety, clinical efficacy and 
valve performance of the ACURATE neo Transfemoral TAVI System in all-comers, high-risk 
TAVI Population. Excellent procedural success, survival, and NYHA development.  
 
Figure 7. Symetis Acurate Neo Aortic Valve. 
 
Boston Scientific Lotus 
The Lotus™ Aortic Valve Replacement System (Boston Scientific Corporation, Natick, MA, 
USA) included a bioprosthetic aortic valve implant consisting of three bovine pericardial 
leaflets attached to a braided nitinol frame with a radiopaque marker and a catheter-based 
system for introduction and retrograde delivery via the femoral artery (Figure 8). The valve 
was pre-attached to the delivery system. The Lotus Valve starts working early in deployment, 
aiding controlled, precise initial positioning, and repositioning or full retrieval at any point 
prior to definitive release if required. Rapid pacing is not required during the implant 
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procedure. The valve was designed to expand radially as the valve shortens during 
deployment. An adaptive seal surrounds the inflow portion of the device and was designed 
to reduce paravalvular regurgitation. The REPRISE II study (63,64) evaluated results of Lotus 
valve. All patients were successfully implanted with a Lotus Valve, and 1-year clinical follow-
up was available for 99.2%. The mean 1-year transvalvular aortic pressure gradient was 12.6 
± 5.7 mm Hg, and the mean valve area was 1.7 ± 0.5 cm2. Over 88% patients had no or trivial 
paravalvular aortic regurgitation at 1 year by independent core lab adjudication, and 97.1% 
of patients were NYHI class I or II. At 1 year, the all-cause mortality rate was 10.9%, disabling 
stroke rate was 3.4%, disabling bleeding rate was 5.9%, with no repeat procedures for valve-
related dysfunction. A total of 31.9% underwent new permanent pacemaker implantation 
at 1 year. 
 
Figure 8. Boston Scientific Lotus trans-catheter heart valve. 
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Post-TAVI monitoring and management 
After TAVI, patients remained in the cardiac intensive care unit for at least 24 hours and 
were monitored for 48-72 hours with particular attention to hemodynamic balance, vascular 
access, renal function, infections and eventual onset of cardiac conduction disturbances 
(especially late atrioventricular block). A transthoracic echocardiography was performed 48 
hours after the procedure and pre-discharge. Twelve-lead electrocardiography was 
performed daily during hospitalization. A chest X-ray was performed during the first 24 hours 
after TAVI and according to clinical need after then. Blood tests were carried out every 8 
hours the first day, then every 12-24 hours. After the procedure, a dual antiplatelet regimen 
of aspirin 100 mg and clopidogrel 75 mg daily for at least 3 months, and then with single 
antiplatelet therapy afterwards. When oral anticoagulant was indicated, patients were 
treated with vitamin K anticoagulant and only one antiplatelet agent. 
 
Follow up and End Points 
Clinical and echocardiographic evaluation was performed at hospital admission, before 
discharge, 1 to 6 months postoperatively, and on a yearly basis thereafter in a TAVI-
dedicated outpatient clinic. In this setting, all patients underwent bidimensional and 
eventually 3-dimensional transthoracic echocardiography using an iE33 echocardiography 
system (Philips Healthcare, the Netherlands), following the recommendations from the 
specific guidelines for echocardiography in transcatheter interventions for valvular heart 
disease (65). If a more detailed evaluation was needed, transesophageal echocardiography 
was performed. For patients unable to come to our hospital for follow-up evaluation (<10%), 
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we performed telephone interviews and asked for a copy of the most recent 
echocardiographic examination. 
Preoperative clinical variables were defined according to the European System for Cardiac 
Operative Risk Evaluation (Euro- SCORE) definitions (27,66). 
Postoperative outcomes and clinical end-points were reported following the updated Valve 
Academic Research Consortium (VARC)-2 definitions (67,68, 69). 
Postoperative aortic regurgitation (AR) was graded as no or trivial AR, mild AR, moderate AR, 
and severe AR. In particular, the presence and severity of AR was based on the evaluation of 
both central and paravalvular components with a combined measurement of total AR. The 
assessment of AR was performed according to current guidelines (65,67,68) using 
quantitative (regurgitant volume, regurgitant fraction, and effective regurgitant orifice area) 
and semiquantitative (diastolic flow reversal in the descending aorta, circumferential extent 
of prosthetic valve paravalvular regurgitation) methods.  
 
VARC-2 Definitions: (69) 
According to VARC-2, we analyzed the following end-points:  
1. All-cause mortality 
Cardiovascular mortality: Any of the following criteria: Death due to proximate cardiac cause 
(e.g. myocardial infarction, cardiac tamponade, worsening heart failure). Death caused by 
non-coronary vascular conditions such as neurological events, pulmonary embolism, 
ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease. All procedure-
related deaths, including those related to a complication of the procedure or treatment for 
a complication of the procedure. All valve-related deaths including structural or non-
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structural valve dysfunction or other valve-related adverse events. Sudden or unwitnessed 
death and death of unknown cause. 
Non-cardiovascular mortality: Any death in which the primary cause of death is clearly 
related to another condition (e.g. tr auma, cancer, suicide) 
2. Myocardial Infarction (MI) 
Peri-procedural MI (≤72 h after the index procedure). New ischemic symptoms (e.g. chest 
pain or shortness of breath), or new ischemic signs (e.g. ventricular arrhythmias, new or 
worsening heart failure, new ST-segment changes, hemodynamic instability, new 
pathological Q-waves in at least two contiguous leads, imaging evidence of new loss of viable 
myocardium or new wall motion abnormality), and elevated cardiac biomarkers within 72 h 
after the index procedure (consisting of at least one sample post-procedure with a peak 
value exceeding 15 times as the upper reference limit for troponin or 5 times for CK-MB. If 
cardiac biomarkers are increased at baseline, a further increase in at least 50% post-
procedure is required and the peak value must exceed the previously stated limit. 
Spontaneous MI (>72 h after the index procedure): detection of rise and/or fall of cardiac 
biomarkers with at least one value above the 99th percentile URL, together with the evidence 
of myocardial ischaemia. Ischeamia was defined as at least one of the following: Symptoms 
of ischaemia ECG changes indicative of new ischaemia (new ST-T changes or new left bundle 
branch block (LBBB)); new pathological Q-waves in at least two contiguous leads; imaging 
evidence of a new loss of viable myocardium or new wall motion abnormality. Also any 
sudden, unexpected cardiac death, involving cardiac arrest. The evidence of fresh thrombus 
by coronary angiography and/or at autopsy. Pathological findings of an acute myocardial 
infarction 
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3. Stroke 
Diagnostic criteria: Acute episode of a focal or global neurological deficit with at least one of 
the following: change in the level of consciousness, hemiplegia, hemiparesis, numbness, or 
sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis 
fugax, or other neurological signs or symptoms consistent with stroke.  
Stroke: duration of a focal or global neurological deficit ≥24 h; or 24 h if available 
neuroimaging documents a new haemorrhage or infarct; or the neurological deficit results 
in death  
TIA (transient ischemic attack): duration of a focal or global neurological deficit < 24 h. 
Stroke classification: 
 Ischaemic: an acute episode of focal cerebral, spinal, or retinal dysfunction caused 
by infarction of the central nervous system tissue  
 Haemorrhagic: an acute episode of focal or global cerebral or spinal dysfunction 
caused by intraparenchymal, intraventricular, or subarachnoid haemorrhage  
 A stroke may be classified as undetermined if there is insufficient information to 
allow categorization as ischaemic or haemorrhagic 
Stroke definitions: disabling or non-disabling stroke 
4. Bleeding 
Life-threatening or disabling bleeding: Fatal bleeding (BARC type 5) or bleeding in a critical 
organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating 
pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) or 
bleeding causing hypovolaemic shock or severe hypotension requiring vasopressors or 
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surgery (BARC type 3b) or overt source of bleeding with drop in haemoglobin ≥5 g/dL or 
whole blood or packed red blood cells (RBCs) transfusion ≥4 unitsa (BARC type 3b) 
Major bleeding (BARC type 3a): Overt bleeding either associated with a drop in the 
haemoglobin level of at least 3.0 g/dl or requiring transfusion of two or three units of whole 
blood/RBC, or causing hospitalization or permanent injury, or requiring surgery and does not 
meet criteria of life-threatening or disabling bleeding 
Minor bleeding (BARC type 2 or 3a, depending on the severity): any bleeding worthy of 
clinical mention (e.g. access site haematoma) that does not qualify as life threatening, 
disabling, or major.  
5. Acute kidney injury (AKI classification) 
Stage 1: Increase in serum creatinine to 150–199% (1.5–1.99 × increase compared with 
baseline) or increase of ≥0.3 mg/dL (≥26.4 mmol/L) or urine output 0.5 mL/kg/h for 6-12 
hours. 
Stage 2: Increase in serum creatinine to 200–299% (2.0–2.99 × increase compared with 
baseline) or urine output 0.5 mL/kg/h for 12-24 hours. 
Stage 3: Increase in serum creatinine to ≥300% (.3 × increase compared with baseline) or 
serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL 
(44 mmol/L) OR Urine output 0.3 ml/kg/h for ≥24 h or anuria for ≥12 h. 
6.  Vascular access site and access-related complications 
Major vascular complications: Any aortic dissection, aortic rupture, annulus rupture, left 
ventricle perforation, or new apical aneurysm/pseudo-aneurysm. Any access site or access-
related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, 
pseudoaneurysm, haematoma, irreversible nerve injury, compartment syndrome, 
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percutaneous closure device failure) leading to death. Life-threatening or major bleeding, 
visceral ischaemia, or neurological impairment. Distal embolization (non-cerebral) from a 
vascular source requiring surgery or resulting in amputation or irreversible end-organ 
damage. The use of unplanned endovascular or surgical intervention associated with death, 
major bleeding, visceral ischaemia or neurological impairment. Any new ipsilateral lower 
extremity ischaemia documented by patient symptoms, physical exam, and/or decreased or 
absent blood flow on lower extremity angiogram. Surgery for access site-related nerve injury 
or permanent access site-related nerve injury  
Minor vascular complications: Access site or access-related vascular injury (dissection, 
stenosis, perforation, rupture, arterio-venous fistula, pseudoaneuysms, haematomas, 
percutaneous closure device failure) not leading to death. Life-threatening or major 
bleedinga, visceral ischaemia, or neurological impairment or distal embolization treated with 
embolectomy and/or thrombectomy and not resulting in amputation or irreversible end-
organ damage. Any unplanned endovascular stenting or unplanned surgical intervention not 
meeting the criteria for a major vascular complication. Vascular repair or the need for 
vascular repair (via surgery, ultrasound-guided compression, transcatheter embolization, or 
stent-graft). 
 
The cumulative end-points were: 
1. Device success: defined as absence of procedural mortality and correct positioning of a 
single PHV into the proper anatomic location and intended performance of the prosthetic 
heart valve (no prosthesis/ patient mismatch and mean aortic valve gradient <20 mm Hg or 
peak velocity <3 m/s and no moderate or severe prosthetic valve regurgitation. 
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2. Early safety (at 30 days): defined as absence of all-cause mortality, all stroke (disabling 
and non-disabling), life-threatening bleeding, AKI (Stage 2 or 3), coronary artery 
obstruction requiring intervention, major vascular complication, valve-related dysfunction 
requiring repeat procedure (BAV, TAVI, or SAVR) 
3. Clinical efficacy (at 1 years): defined as absence of all-cause mortality; all-stroke (disabling 
and non-disabling); requirement of hospitalization for valve-related symptoms; worsening 
CHF, NYHA class III or IV; valve-related dysfunction (mean aortic valve gradient >20 mm Hg, 
effective orifice area (EOA) ≤ 0.9–1.1 cm2 or dimensionless valve index <0. 35 (or both), or 
moderate or severe prosthetic valve regurgitation.  
4. Time-related valve safety: Structural valve deterioration: calve-related dysfunction (mean 
aortic valve gradient ≥20 mmHg, EOA ≤0.9–1.1 cm2c or moderate or severe prosthetic valve 
regurgitation); requiring repeat procedure (TAVI or SAVR). Prosthetic valve endocarditis; 
prosthetic valve thrombosis; thrombo-embolic events (e.g. stroke). 
5. Late prosthesis failure was defined as mean aortic valve gradient ≥20 mmHg, effective 
orifice area ≤0.9–1.1 cm2 and/or Doppler velocity index <0.35 m/s and/or moderate or 
severe prosthetic valve regurgitation; the presence of leaflets thrombosis or valve 
endocarditis was excluded by computed tomography (CT) scan or autopsy. 
In the table 4 were reported the 2017 ECC/EACTS guideline definitions for the prosthetic 
valve dysfunction. 
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Table 4. Classification of prosthesis valve dysfunction (2017 ECC/EACTS guideline). 
 
 
Statistical analysis 
Quantitative variables were analyzed descriptively, reporting mean ± standard deviation 
(SD) in case of normal distribution, median and 25th to 75th percentile [interquartile range 
(IQR)] otherwise. The risk-classes groups were compared with Student’s t-test or Wilcoxon 
rank sum test, as appropriate. Categorical variables were reported as numbers and 
percentages and compared between groups using Chi-square or Fisher’s exact tests, as 
appropriate. Survival analysis was conducted with the Kaplan-Meier method. Cox regression 
was used to identify univariate predictors of events from the major baseline and procedural 
characteristics. Variables with P<0.15 at the univariate analysis were subsequently 
considered in a multivariable Cox regression model to identify independent predictors of 
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death. Results of the Cox regression were reported as hazard ratio (HR), 95% confidence 
interval (CI) and P values. Statistical analysis was conducted with SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA) for Windows. 
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RESULTS 
The overall population comprised 482 patients with severe symptomatic AS (95%) or aortic 
bioprosthesis dysfunction (5%). All of them were retrospectively divided in four risk classes 
(low, intermediate, high and prohibitive). 
Groups were similarly represented; in fact, 115 (23.9%) patients were at low risk with STS 
score < 4, 112 (23.2%) at intermediate risk with STS score 4-8, 131 (27.2%) at high risk with 
STS score > 8 and the remaining 124 (25.7%) at prohibitive risk. 
Most of the prohibitive cases (91%) had specific anatomic or technical contraindications to 
surgery as reported in Table 5. Only one (0.8%) patient presented a STS score with a 1-year 
mortality risk >50% and 15 (12%) suffered of at least three major organ disorders. Some 
patients present more than one clinical contraindication. 
 
Table 5. Anatomic or technical SAVR contraindication in prohibitive patients 
SAVR Contraindications in prohibitive population n (%) 
Porcelain aorta 64 (52%) 
Hostile chest 43 (35%) 
Connective tissue disease 7 (6%) 
Previous chest radiotherapy 21 (17%) 
 
Over time, the group distributions significantly changed with more high and prohibitive risk 
patients in the first year compared to more low and intermediate ones in the last years 
(figure 9). 
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Figure 9. Distribution of patients for risk-classes during years 2007-2017 
 
Table 6 reported baseline clinical characteristics of the populations. Mean age was 80.4±6.6 
years old and prohibitive-risk patients were significantly younger (p<0.001) than low, 
intermediate and high risk ones (76.9±7.7, 80.4±4.8, 82.0±6.8 and 82.2±5.2 years old, 
respectively). 
Overall, more than half of the cases (64%) showed New York Heart association (NYHA) 
functional class III or IV, with a significant lower rate in low-risk patients. One third of the 
population suffered for angina and syncope occurred in 17%, without differences among 
groups. 
Previous myocardial infarction, kidney and chronic obstructive pulmonary disease were 
significantly less reported in low-risk group. The rate of neoplasia was significantly higher in 
prohibitive risk group with respect to other ones, ie 23% vs 15% (high), 11% (intermediate) 
and 11% (low). 
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Table 6. Baseline characteristics. 
 All 
patients 
Low risk Intermediate 
risk 
High risk Prohibitive 
risk 
p-
value 
N° of patients 482 24%(115) 23%(112) 27%(131) 26%(124) 0.456 
Age (years) 80.35±6.60 80.41±4.84 82.04±6.93 82.15±5.21 76.86±7.65 <0.001 
Sex (male) 45% (217) 53% (61) 40% (45) 43% (56) 44% (55) 0.226 
BMI (kg/m2) 26.56±6.16 26.90±3.99 25.62±3.85 27.05±9.40 26.59±5.07 0.084 
STS score 9.36±8.99 2.82±0.73 5.62±1.15 18.82±9.15 8.81±8.83 <0.001 
NYHA 
functional class 
     0.002 
I 8% (38) 12% (13) 8% (9) 2% (3) 11% (13)  
II 28% (134) 36% (41) 29% (33) 27% (35) 20% (25)  
III 53% (251) 49% (55) 47% (53) 60% (78) 53% (65)  
IV 11% (53) 4% (4) 15% (17) 10% (13) 16% (19)  
CCS grading of 
angina pectoris 
     0.679 
0 72%(344) 78% (88) 75%(84) 68% (87) 69% (85)  
1 2% (8) 1% (1) 2% (2) 2% (2) 2% (3)  
2 12% (56) 12%(14) 9% (10) 11% (14) 15% (18)  
3 9% (45) 4% (5) 10% (11) 13% (17) 10% (12)  
4 5% (24) 4% (5) 4% (5) 6%(8) 5% (6)  
Syncope 17% (84) 12% (14) 23% (26) 19% (25) 15% (19) 0.14 
Hypertension 90%(435) 89%(102) 90% (101) 92%(121) 
 
 
90%(111) 0.787 
Dyslipidemia 63% (301) 62% (71) 54% (61) 65% (85) 
 
 
68% (84) 0.182 
Smoking history 27% (129) 23% (26) 32% (36) 26% (34) 27% (33) 0.438 
Diabetes 28% (133) 23% (27) 25% (28) 34% (44) 27% (34) 0.273 
Previous MI 17% (82) 5% (6) 19% (21) 21% (28) 22% (27) 0.001 
Coronary artery 
disease 
55% (266) 51% (59) 56% (63) 55% (71) 59% (73) 0.654 
Previous PCI 31% (148) 26% (30) 28% (31) 37% (48) 31% (39) 0.294 
Previous cardiac 
surgery 
18% (88) 7% (8) 17% (19) 18% (23) 31% (38) 
 
<0.001 
Previous CABG 12% (58) 4% (5) 11% (12) 12% (16) 20% (25) 0.002 
Previous BAV 4% (17) 3% (3) 5% (6) 3% (4) 3% (4) 0.681 
Carotid artery 
stenosis > 50% 
30% (139) 27% (29) 36% (39) 24% (30) 34% (41) 0.144 
CHF 43%(209) 28% (32) 50% (56) 51% (67) 44% (54) <0.001 
Cerebrovascular 
accident 
12% (56) 8% (9) 15% (17) 9% (12) 15% (18) 0.207 
Renal failure 
eGFR < 60 
57%(275) 
 
48% (55) 68% (76) 66% (86) 47% (58) <0.001 
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Creatinine 
clearance 
57.0±21.6 62.1±17.1 52.9±22.2 53.2 ±22.2 59.9±22.7 <0.001 
COPD 26%(126) 13% (15) 27% (30) 37% (48) 27% (33) <0.001 
Atrial 
fibrillation 
34%(163) 33% (38) 36% (40) 31% (41) 36% (44) 0.857 
Pacemaker  9% (41) 9% (10) 10% (11) 7% (8) 10% (12) 0.772 
Neoplastic 
disease 
15% (72) 15% (17) 11% (12) 11% (15) 23% (28) 0.036 
Neurological 
dysfunction 
8% (37) 11% (12) 5% (6) 6% (8) 9% (11) 0.375 
Endocarditis 1% (3) 1% (1) 1% (1) 1% (1) 0% (0) 0.786 
Liver failure 2% (11) 2% (2) 3% (3) 2% (2) 3% (4) 0.79 
 
 
The main echocardiographic findings were listed in the table 7. 
 
Table 7. Baseline echocardiographic data. 
 All 
patients 
Low risk Intermedi
ate risk 
High risk Prohibitive 
risk 
p-
value 
AVA (cm2) 0.79±0.24 0.76±0.21 0.78±0.23 0.82±0.27 0.80±0.21 0.199 
iAVA(cm2/m2) 0.45±0.13 0.43±0.13 0.45±0.14 0.47±0.14 0.46±0.12 0.043 
Peak transvalvular 
gradient (mmHg) 
73.3±23.2 76.8±24.0 75.5±25.0 72.1±21.8 69.4±21.5 0.186 
Mean transvalvular 
gradient (mmHg) 
44.8±15.1 48.2±15.3 46.5±16.4 42.9±14.2 42.3±14.0 0.027 
LVEF(%) 54.9±12.2 55.9±10.9 55.1±13.0 53.5±12.1 55.3±12.8 0.409 
End diastolic volume 
(ml/m2) 
66.7±24.2 65.5±23.4 66.2±26.0 65.3±21.4 69.7±25.9 0.556 
Pulmonary artery 
pressure (mmHg) 
40.5±13.8 37.7±11.9 41.3±13.1 41.4±14.6 41.2±15.0 0.316 
Aortic regurgitation      0.626 
   None or trivial 33% (153) 41% (44) 34% (37) 31% (40) 26% (32)  
   Mild 44% (205) 38% (41) 43% (47) 43% (54) 52% (63)  
   Moderate 18% (83) 17% (18) 17% (19) 20% (25) 17% (21)  
   Severe 5% (25) 5% (5) 6% (6) 6% (8) 5% (6)  
Mitral regurgitation 
>2 
29% (140) 23% (26) 34%(38) 32% (42) 27% (34) 0.227 
Tricuspid 
regurgitation >2 
22% (108) 18% (21) 26% (29) 22% (29) 23% (29) 0.574 
 
Echocardiographic data showed few significant differences in terms of index AVA (mean 
0.46±0.12 cm2/m2) and mean transvalvular gradient (mean 44.8±15.1 mmHg) among groups, 
whereas LVEF (mean 54.9±12.2%) and end diastolic volume (mean 66.7±24.2 ml/m2). 
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Procedural and in-hospital data. 
TAVI procedure details were showed in Table 8. In 74% of cases, TF access was used without 
significant differences among groups (Figure 10). 
 
 
Figure 10. Access type. 
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Table 8. Procedural Data. 
 All 
patients 
Low risk Intermedia
te risk 
High 
risk 
Prohibitiv
e risk 
p-
value 
Access      0.204 
   TF 74% (356) 81% (93) 79% (88) 73% (95) 65% (80)  
   TA 19% (93) 18% (21) 16% (18) 16% (21) 27% (33)  
Device       <0.001 
CoreValve 18% (88) 3% (4) 21% (23) 22% (29) 26% (32)  
Sapien/Sapien XT 51% (245) 30% (35) 56% (63) 60% (79) 55% (68)  
Sapien 3 17% (82) 26% (30) 15% (17) 17% (22) 10% (13)  
Lotus 11% (55) 31% (35) 8% (9) 1% (1) 8% (10)  
Symetis Acurate 2% (9) 8% (9) 0% (0) 0% (0) 0% (0)  
CoreValve Evolut 
R 
1% (3) 2% (2) 0% (0) 0% (0) 1% (1)  
Valve in valve  5% (23) 3% (4) 4% (5) 5% (6) 6% (8) 0.746 
Valve pre-
dilatation 
74% (353) 49% (56) 75% (82) 93% 
(120) 
78% (95) <0.001 
Prosthesis post-
dilatation  
12% (59) 14% (16) 11% (12) 11% (15) 13% (16) 0.88 
 
Most of the patients received an Edwards Sapien models (Figura 11). CoreValve, Sapien and 
Sapien XT were more frequently implanted in prohibitive, high and intermediate risk classes. 
In contrast, second generation devices, such as Lotus and Sapien 3 valves, were more used 
in low-risk group (p<0.001) (Figure 12). Only 9 Symetis Acurate and 3 CoreValve Evolut R 
were implanted, 10 of them in low risk patients. Overall, 68% of prosthesis were balloon-
expandable and the remaining self-expandable. 
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Figure 11. THV type in overall population. 
 
 
Figure 12. THV types according risk-classes. 
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Pre-dilatation of aortic valve was performed in 74% of patients, ranging from 49% of low risk 
to 93% of high risk ones (p <0.001). Pre-dilatation use decreased over time from >90% in the 
first years to <20% in the last ones (p<0.001 (Figure 13). No differences in the prosthetic 
post-dilatation were present. 
 
Figure 13. Aortic valve pre-dilatation over the time.  
 
Procedural and in-Hospital outcomes are shown in Table 9.  
Procedural success was high (95%) even in high-risk patients and intraoperative mortality 
was low (<1%). Complications did not differ among groups, with the only exception for 
bleeding. In fact, severe bleeding (major and life-threatening) occurred more frequently in 
high-risk patients (29% vs, p=0.015). Hospitalization was shorter in low-risk patients (12.7 ± 
8.8) compared to intermediate (17.2 ± 13.4), high (16.8 ± 12.6) and prohibitive (16.6 ± 12.4) 
ones (days, p=0.001). The rate of permanent pacemaker implantation was 17%, without 
differences among groups. 
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Table 9. Procedural and in-hospital outcome. 
 All pts Low risk Intermedi
ate risk 
High risk Prohibitive 
risk 
p-
value 
Procedural 
mortality 
1% (4) 0% (0) 0% (0) 2% (3) 1% (1) 0.153 
Device success 95% (458) 95%(109) 95%(106) 94%(123) 97% (120) 0.746 
Stroke 1% (3) 0% (0) 1% (1) 1% (1) 1% (1) 0.806 
TIA 1% (7) 1% (1) 2% (2) 2% (3) 1% (1) 0.717 
MI 1% (4) 1% (1) 2% (2) 0% (0) 1% (1) 0.5 
Major vascular 
complications 
11% (54) 10% (11) 11% (12) 17% (22) 7% (9) 0.1 
Bleeding      0.015 
  Minor 17% (82) 19%(22) 15%(17) 17%(22) 17% (21)  
  Major 17% (79) 12% (14) 13% (14) 23% (30) 17% (21)  
  Life-threatening 3% (15) 0% (0) 5% (6) 6% (8) 1% (1)  
AKI Stage      0.162 
   1 7% (34) 6% (7) 8% (9) 5% (7) 9% (11)  
   2 4% (21) 1% (1) 5% (6) 7% (9) 4% (5)  
   3 3% (14) 0% (0) 3% (3) 5% (6) 4% (5)  
III - AV block  13% (60) 12% (14) 16% (18) 11% (14) 11% (14) 0.589 
Ventricular 
fibrillation 
3% (12) 2% (2) 1% (1) 3% (4) 4% (5) 0.416 
Pacemaker 
implantation 
17% (81) 17% (19) 20% (22) 15% (19) 17% (21) 0.742 
Conversion to 
surgery 
1% (7) 0% (0) 1% (1) 3% (4) 2% (2) 0.232 
Ventricular 
septal 
perforation 
1% (3) 0% (0) 0% (0) 2% (2) 1% (1) 0.362 
Cardiac 
tamponade 
2% (11) 0% (0) 2% (2) 5% (6) 2% (3) 0.117 
Aortic dissection 1% (4) 0% (0) 2% (2) 2% (2) 0% (0) 0.259 
Device 
embolization 
1% (7) 0% (0) 2% (2) 2% (3) 2% (2) 0.485 
TAVI in TAVI 2% (9) 1% (1) 3% (3) 2% (3) 2% (2) 0.745 
Coronary 
obstruction 
1% (4) 1% (1) 2% (2) 0% (0) 1% (1) 0.5 
Length of 
hospital stay 
(days) 
15.9±12.1 12.7±8.8 17.2±13.4 16.8±12.6 16.6±12.4 0.001 
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Echocardiographic data at 48 hours after TAVI procedure are reported in Table 10. 
Transvalvular aortic mean gradient (11.2±5.2 mmHg) significantly decreased with 
corresponding improvement of effective orifice area (2.1±1.3 cm2) without differences 
among groups. Significant paravalvular leak (PVL), defined as a regurgitation more than 
moderate, occurred in 49 (10%) of patients and in 60% of cases in the first three years of 
TAVI program (2007-2009).  
 
Table 10. Echocardiographic data at 48 hours after TAVI procedure. 
 All pts Low risk Intermedi
ate risk 
High risk Prohibitiv
e risk 
p-
value 
End diastolic 
volume (ml/m2) 
65.3±22.2 63.5±20.3 64.9±25.7 65.1±20.3 67.6±22.7 0.437 
LVEF (%) 55.7±11.7 56.9±10.3 56.2±11.7 54.7±12.9 55.0±11.5 0.487 
AVA (cm2) 2.06±0.7 2.01±0.6 2.09±0.6 2.1±0.8 1.98±0.6 0.21 
iAVA (cm2/m2) 1.20±1.1 1.13±0.3 1.22±0.3 1.33±2.1 1.13±0.3 0.165 
Peak gradient 
(mmHg) 
20.42±8.9 20.33±9.3 20.84±9.1 21.08±9.3 19.46±7.7 0.619 
Mean gradient 
(mmHg) 
11.22±5.2 11.68±5.3 11.51±5.2 11.14±5.6 10.63±4.7 0.24 
PVL      0.792 
   1 19% (87) 14% (16) 21% (21) 21% (25) 21% (25)  
   2 28% (126) 28% (32) 28% (28) 31% (37) 24% (29)  
   3 9% (42) 9% (10) 8% (8) 10% (12) 10% (12)  
   4 1% (5) 1% (1) 0% (0) 1% (1) 3% (3)  
Mitral valve 
regurgitation > 2 
23% (101) 20% (21) 26% (25) 26% (31) 21% (24) 0.62 
Tricuspid valve 
regurgitation > 2 
23% (98) 17% (18) 28% (27) 26% (30) 21% (23) 0.181 
 
Early and 1-year clinical and hemodynamic outcomes.  
Thirty-day clinical and hemodynamic results are reported in Table 11. Overall mortality was 
3% with a significantly (p= 0.048) lower rates in low (any patients) and prohibitive risk groups 
(2%) compared to intermediate (4%) and high (6%) risk ones. Others adverse events were 
infrequent (stroke 2%, MI 2%, CHF 4%) and did not differ among groups. Overall MACE were 
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10% and resulted significantly lower in the low risk group compared to the others. Early-
safety at 30 days was 82% and resulted significantly higher (p=0.049) in low and prohibitive 
risk groups (88% and 86%, respectively) versus intermediate (80%) and high (76%) risk ones. 
In addition, low-risk class predicted early-safety with respect to other groups (HR 2.4, CI 1.19-
4.87, p= 0.05).  
Echocardiography data confirmed the efficacy of TAVI to reduce mean transvalvular aortic 
gradient (10.4±4.7 mmHg) with an improvement in effective orifice area (1.9±0.4 cm2) in 
absence of differences among groups. Significant PVL was observed in 13% of the patients, 
without differences among groups.  
 
Table 11. Clinical and hemodynamic outcome at 30 days 
 All pts Low risk Intermedia
te risk 
High risk Prohibitive 
risk 
p-
value 
Mortality 3% (16) 0% (0) 4% (5) 6% (8) 2% (3) 0.048 
All stroke 2% (11) 0% (0) 2% (2) 4% (5) 3% (4) 0.191 
MI 2% (9) 1% (1) 3% (3) 2% (3) 2% (2) 0.75 
CHF 4% (17) 2% (2) 5% (6) 2% (3) 5% (6) 0.344 
MACE 10% (50) 3% (4) 12% (13) 15% (19) 11% (14) 0.034 
Early safety 82% (389) 88% (100) 80% (87) 76% (99) 86% (103) 0.049 
AVA (cm2) 1.85±0.43 1.87±0.43 1.77±0.44 1.88±0.39 1.86±0.45 0.15 
iAVA (cm2/m2) 1.05±0.27 1.06±0.25 1.02±0.30 1.07±0.28 1.05±0.27 0.498 
Mean gradient 
(mmHg) 
10.4±4.7 10.9±4.6 10.5±5.2 9.9±4.8 10.3±4.1 0.381 
PVL      0.205 
   1 21% (82) 15% (15) 26% (24) 23% (23) 20% (20)  
   2 27% (106) 26% (26) 26% (24) 28% (28) 28% (28)  
   3 13% (50) 8% (8) 11% (10) 14% (14) 18% (18)  
   4 0% (1) 0% (0) 0% (0) 1% (1) 0% (0)  
 
Table 12 shows clinical and hemodynamic results at 1 years and the number of patients at 
risk at 1 year was 331. Overall mortality was 14% with significant (p=0.008) higher rates in 
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high (19%) and intermediate (21%) risk groups compared to low (6%) and prohibitive (7%) 
risk ones. Cardiovascular death was 7% with statistical trend in favor of low (1%) and 
prohibitive (5%) risk patients when compared to intermediate and high risk ones (13%). One-
year clinical efficacy was 73% without differences among groups. Others clinical and 
hemodynamic features did not differed. 
 
Table 12. Clinical and hemodynamic outcome at 1 year 
 All pts Low risk Intermediate 
risk 
High risk Prohibitive 
risk 
p-
value 
Mortality 14% (50) 6% (3) 21% (19) 19% (21) 7% (7) 0.008 
Cardiovascular 
mortality 
7% (33) 1%(2) 13% (12) 13% (14) 5% (5) 0.068 
All stroke 4% (14) 0% (0) 2% (2) 6% (6) 6% (6) 0.283 
MI 4% (13) 5% (2) 4% (3) 6% (6) 2% (2) 0.555 
CHF 18% (62) 17% (8) 16% (14) 14% (15) 25% (25) 0.23 
MACE 32% (114) 29% (15) 32% (29) 36% (40) 29% (30) 0.758 
Clinical 
efficacy  
73% (277) 68% (40) 73% (65) 77% (95) 72% (77) 0.575 
Prosthesis 
dysfunction 
9% (31) 9% (10) 7% (7) 11% (13) 9% (11) 0.76 
AVA (cm2) 1.75±0.34 1.83±0.35 1.72±0.30 1.74±0.29 1.74±0.39 0.619 
iAVA (cm2/m2) 1.03±0.61 1.04±0.25 1.05±0.34 1.02±0.20 1.03±0.25 0.835 
Mean gradient 
(mmHg) 
10.7±5.3 11.5±5.2 9.8±4.1 10.2±4.2 11.6±6.7 0.14 
PVL      0.269 
   1 31% (66) 14% (4) 38% (20) 36% (22) 30% (20)  
   2 28% (59) 24% (7) 30% (16) 28% (17) 28% (19)  
   3 10% (21) 10% (3) 8% (4) 10% (6) 12% (8)  
   4 1% (2) 3% (1) 2% (1) 0% (0) 0% (0)  
 
Kaplan Meier (KM) survival curves are reported in figure 14. 
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Figure 14. Kaplan-Meier survival curves at 1 year. 
 
Long-term clinical outcome 
Median follow-up in the overall population was 3.1 years (13 days-9 years), with a 94% of 
completeness. The duration was significantly shorter in low risk patients (2.0±1.9 years) 
compared to overall population (3.2±2.9 years). Overall, clinical outcome at 5-years is 
showed in table 13. 
Table 13. Long-term clinical outcome. 
 All patients 
Mortality 52% (131) 
Cardiovascular mortality 17% (42) 
All stroke 7% (18) 
MI 6% (15) 
CHF 33% (83) 
MACE 53% (133) 
 
Overall death occurred in 131 (52%) patients at 5 years and the KM curves (Figure 15) 
showed a significantly improved survival only in low risk patients. 
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Figure 15.Long term KM survival curves free from overall death. 
 
With regard to cardiovascular death, low and prohibitive risk groups showed better survival 
than intermediate and high risk ones (Figure 16). 
 
Figure 16. Long term KM survival curves free from cardiovascular death. 
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A significant and sustained improvement in NYHA functional class was observed in all risk 
groups (Figure 17). 
 
Figure 17. NYHA functional status. Longitudinal trend in NYHA functional status before and 
after TAVI, according to risk-classes. 
 
The significant results of multivariate analysis to predict death are showed in table 14. CHF 
(HR 1.7, p=0.01), neoplastic disease (HR 1.67, p =0.05) and creatinine values in mg/dl (HR 
1.13, p=0.001) were pre-procedural independent predictor of death. Severe bleeding (major 
or life tethering) (HR 4.57, 95% CI 1.48-14.06, p=0.05) and any AKI stage (HR 2.46, p=0.001) 
were post-procedural independent predictor of death. The risk class did not result to 
significantly predict death at multivariate analysis (low HR 0.49, 95% CI 0.18-1.33, 
intermediate HR 0.50, 95%CI 0.68-1.82, high HR 0.90, 95%CI 0.68-1.82 and prohibitive HR 
0.90, 95%CI 0.53-1.52). 
Table 14. Independent predictor of death at multivariate analysis. 
  HR ICs.  P 
CHF 1.7755 1.1543 2.7309 0.01 
Neoplastic disease 1.6664 0.99589 2.7885 0.05 
Severe bleeding 4.5675 1.4834 14.064 0.05 
Creatinine pre-procedure (mg/d). 1.1259 1.0261 1.2353 0.01 
AKI  2.5498 2.4588 1.2944 4.6705 
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Long-term hemodynamic outcome and prosthesis dysfunction. 
Prosthetic hemodynamic performances at last follow-up was reported in Table 15 and Figure 
18.  
Table 15. Prosthesis hemodynamic performance at long term follow-up 
 All patients 
Prosthesis dysfunction 11.4% (38) 
Aortic valve area (cm2) 1.72±0.41 
Indexed valve area (cm2/m2) 1.03±0.61 
Mean gradient (mmHg) 10.9±5.1 
PVL > 2 11% (24) 
 
 
Figure 18. Variation of transaortic gradient (peak and mean) and effective orifice area of 
patient undergoing TAVI procedure 
 
Trans-prosthetic gradient and effective orifice area remained stable over time in all the 
groups. Post-procedural PVL was significant (>2) in 11% of patients. Among patients with 
trivial or mild PVL, no changes in leak severity were observed over time. Considering patient 
at risk at 1 year, 31 patients (9%) had a prosthetic dysfunction that appeared in the first year 
after procedure. All these patients had a high transvalvular mean gradient (mean 15 mmHg) 
or almost a mild PVL after procedure. Overall prosthesis dysfunction at long-term was 11.4% 
(Figure 19) and late prosthesis failure occurred in 7 patients (2.1%). CT scan or autopsy, 
whenever possible, confirmed structural valve deterioration. Two patient developed both 
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increased trans-prosthetic gradients and severe intra-prosthetic regurgitation at 3 and 4 
years. One case underwent a valve-valve procedure. Three patients had valve restenosis 
(mean gradients 38 and 43 mmHg, 25 mmHg, respectively) after 4 years. Two patients 
developed a severe intra-prosthetic regurgitation at 3 and 7 years. All these patients were 
treated conservatively because of their high frailty status.  
 
 
Figure 19. Prosthesis dysfunction 
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DISCUSSION 
 
The main results of the following single center study analyzing safety and efficacy of 482 real 
world patients treated by TAVI for symptomatic AS or aortic bio-prosthesis dysfunction as 
function of different surgical risk scores are: 
I) The distribution of the population according to surgical risk score was similarly 
represented (23.9% low-risk, 23.2% intermediate-risk, 27.2% high-risk and 25.7% 
prohibitive-risk), but over the time the group distributions significantly changed with more 
low- and intermediate-risk patients in the last years. 
II) TAVI was safe and effective at 1-year, with low rates of mortality and adverse events 
regardless of the surgical risk.  
III) At longer follow-up mortality rate was significantly lower in low-risk patients.  
IV) Pre-procedural CHF, neoplastic diseases, pre-procedural creatinine, post-procedural 
severe bleedings and post-procedural AKI were independent predictors of mortality.  
V) THV performance after the procedure was excellent and stable over time with low 
rate of late prosthesis dysfunction (<2.5%). 
 
The device success in our analysis resulted to be satisfactory (95%) as also reported by other 
registries as SOURCE (93.8%), SOURCE XT (94.5%), SOURCE 3 (98.3%) and French registry 
(FRANCE-2 96.9%) (70,71,72). These data confirm the feasibly of TAVI in almost all cases, 
despite the apparent complexity of the procedure. The risk class did not influence the 
occurrence of procedural mortality (1%) or others complications, with the only exception of 
severe bleeding that was higher in high-risk patients (p=0.015) as showed by other studies 
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(73-74). The significant reduction of the hospitalization time in low-risk patients (12.7±8.8 
days vs 15.9±12.1 days on average, p=0.001) is not surprising and may be explained by the 
younger age and the lower rate of previous MI (p< 0.001), CHF (p<0.001), chronic kidney 
disease (p<0.001) and COPD (p<0.001) in this group compared to other ones. 
As in previous studies (38,45,71), early safety was achieved in most of patients and 
significantly differed among groups (low-risk 88%, prohibitive-risk 86%, intermediate-risk 
80%, high-risk 76%, p = 0.049). This dissimilarity may be explained by the fact that early 
mortality and bleeding differed as well. 
In our study, the 30-day mortality was 3% similarly to other trials and registries in which it 
ranged from 1% (SOURCE-3 1.1%, NOTION registry 2.1%, SURTAVI 2.2%, PIVOTAL trial with 
CoreValve 3.3%, PARTNER TAVI arm 3.4%) to nearly 10% in multicentric FRANCE-2 registry, 
8.4% in CoreValve ER (38,45,48,59,71,72). Similar data were observed in high-risk patients 
undergoing traditional surgery (PARTNER SAVR arm 6.5%) (38). Moreover, the mortality risk 
estimated by STS score looked to be higher than our results in all risk groups, confirming 
poor calibration for mortality estimation in TAVI patients (75,76).  
The low-risk group showed no death at 30 days and a 1-year mortality rate of 6%. This 
observation was comparable with data available from other studies in which low risk 
patients’ mortality ranged from 2-3% at 30 days to 5-10% at one year. (73-77). Even the 
prohibitive-risk group showed low mortality rates, 2% at 30 days and 7% to 1 year. This result 
could be explained by the fact that most of these patients underwent TAVI because of 
technical contraindications to SAVR more than increased comorbidities. A similar effect 
emerged also in other studies (69,77) in which technically inoperable patients had better 
outcomes than clinically inoperable ones. Thus, for example, our prohibitive-risk group was 
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composed of younger patients with a higher rate of neoplastic disease and life expectancy 
>1 year, instead they should have been excluded from the program. 
In high-risk cases, the mortality at 30-days was 6% and at one year 19%. Data Literature 
reported discordant data in this group of patients. In fact, some studies showed similar rates 
of death (73,74) but in other ones the mortality rate was higher, up to 34% at 1-year (77-79). 
In our study, the intermediate-risk group’s mortality was comparable to the high-risk one. 
However, in other studies survival was improved (74,77,80) and this dissimilarity could be 
due to different characteristics of the population and nonhomogeneous criteria for risk 
classes stratification. Finally, the worse prognosis of intermediate- and high-risk classes 
could be associated to the older age and the higher rate of CHF, kidney failure and chronic 
lung disease that were independent predictors of mortality (81-85).  
Survival free from MACE at 30 days was more favorable in the low-risk group (3%) than other 
ones (intermediate 12%, high 15%, prohibitive 11%, p = 0.034). This effect was mainly caused 
by the higher rate of mortality and severe bleeding in the former group with respect to the 
latter ones. Subsequently, after 1 year the statistical significance (p=0.758) was lost. The 
increased mortality of intermediate- and high-risk patients could be explained by advanced 
age and multiple comorbidities, as previously described (86). Overall stroke rate at 1 year 
was 4%, as shown in earlier studies (45,80), and no cerebrovascular events occurred in the 
low-risk group (p = 0.283). 
At one year, 90% of patients were asymptomatic for dyspnea with NYHA 1-2 class (p = 0.106). 
Less than 20% of cases were re-hospitalized for CHF and nearly half of these patients 
presented severe mitral regurgitation consistently with previous data (85). 
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The global mortality at 5 years was 52% (131 patients) according to Chakos systematic review 
(86) that analyzed 13857 patients with 5-years mortality rate of 48%. The KM survival curves 
showed a significantly improved survival only in low-risk group. However, multivariate 
analysis did not confirm low-risk class as significant predictor of survival (HR 0.49 for 
mortality, p= 0.49). The different duration of follow-up and the small number of patients at 
risk after 2 years in low-risk group could justify this result. In fact, the median follow-up in 
the overall population was 3.1 years (30 days-9 years) and the follow-up duration differed 
among the groups, being significantly shorter in low-risk patients compared to other ones 
(mean 2.0±1.9 years vs 3.2±2.9 years overall). 
After 1 year, the survival of the prohibitive-risk group decreased progressively and tended 
to match high- and intermediate-risk outcomes. This result could be explained by the higher 
rate of associated diseases that affected these patients. In particular, neoplastic diseases 
were frequent and resulted to be an independent predictor of mortality. As shown in Figure 
13, also the KM curve outlined that most of death in the prohibitive-risk group were non-
cardiovascular related. Similar results were observed also in the 5-year analysis of PARTNER 
1 trial, in which over 2/3 of the deaths were non-cardiovascular (43). 
The independent predictor of long-term mortality at multivariate analysis were few pre-
procedural features and post-procedural complications. Chronic kidney disease (creatinine 
clearance < 60ml/min/1.73m”) was one of the more frequent comorbidities in high- and 
intermediate-risk patients compared to low- and prohibitive-risk ones (respectively, 66% and 
68% vs 48% and 47%, p < 0.001) . The multivariate analysis individuated pre-procedural 
creatinine value as predictor of death with HR of 1.13 (p<0.01) as reported in PARTNER trial 
and registries (38, 88). In our study, we observed that the rate of post-procedural AKI was 
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14% and that any AKI stage resulted to be an independent predictor of mortality with HR of 
2.46 (p=0.001). Also in this case, several trials and registries reported similar results and the 
significant impact of kidney dysfunction on early and long-term survival (82-93). 
In our center, active cancer with life expectancy <1 year represented a contraindication to 
TAVI and patients with a previous cancer were enrolled only after a complete oncologic 
evaluation. The rate of preprocedural neoplastic disease in the study population was 15% 
with significant higher rate in the prohibitive group (23%, p= 0.036). Cancer was the third 
cause of death in our study and independently predicted mortality (HR 1.67, p = 0.05). 
Several reports confirmed this observation and the influence of neoplastic disease in this 
setting (93-95). 
At least one pre-procedural CHF event requiring hospitalization occurred in 43% of the study 
population and it was less frequent in low-risk patients (28%, p < 0.001). To note, pre-
procedural CHF was also an independent predictor of mortality, HR 1.7 (p=0.01).  
Many studies and registries reported that severe bleeding after TAVI procedure increased  
hospitalization time and impacted on early mortality (90,91,93,96). In fact, also in our study 
major and life threatening bleeding represented a strong independent predictor of mortality 
(HR 4.7, p = 0.05). 
TAVI procedure allowed a significant reduction in transvalvular aortic gradient, which was 
stable over time. Consequently, the effective orifice area improved immediately after TAVI, 
achieving values that were even better than those obtained with conventional surgery, both 
for stented and stentless prosthesis (97). This excellent hemodynamic performance 
decreased the prosthesis-patient mismatch phenomenon (4.98%) with even improved 
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results in case of small aortic annulus (97). While the transprosthetic gradient was stable 
over time, the effective orifice area showed a slight decrease at long-term follow-up. This 
event may be justified by the fact that the effective orifice area estimation was not well 
defined and so there could have been an intra- and inter-observer variability during time 
(98). However, this result was comparable to 5-year echocardiographic data of the PARTNER 
1 trial that showed that the mean THV gradient does not change throughout 5 years, with 
very few (<2%) hemodynamic outliers needing re-operation (99). 
In our study the cumulative rate of prosthesis dysfunction was 11.4% and occurred during 
the first year after TAVI in most cases (7.9%). Thereafter, late prosthesis dysfunction 
decreased to 2.1%. Similarly, PARTNER 1 (99) and Barbanti and colleagues study (88) 
reported late prosthesic valve failure at 5 year in 1.4% of the cases. SAVR with pericardial 
bioprosthesis showed that freedom from prothestic deterioration at 15 and 20 years was 
78.6% and 48.5%, respectively (100). However, at present, the strongest argument against 
broadening TAVI indication to younger patients remains undoubtedly valve durability. In 
fact, the low survival rate of current TAVI patients is attributable to the advanced age and 
the multiple comorbidities more than to valve failure. On average, 5-year THV hemodynamic 
data are favorable and comparable to surgical bioprosthesis (43,100,101), and certainly 
sufficient for the currently treated AS patients, considering the mean life expectancy of the 
eighty years old patients (i.e. <4–5 years after TAVI) in most Western countries. After that, 
surgical bioprosthesis are known to degenerate within 10 to 20 years and this phenomenon 
was highly associated to age (101). Notably, it has been hypothesized that THV durability 
might be shorter than surgical bioprostheses because of leaflet crimping, torsion during 
delivery, balloon dilation, possible incomplete, non-circular THV expansion with subsequent 
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asymmetric leaflet opening and increased sheer stress (102-104). Finally, prosthesis 
dysfunction was similarly observed in the different risk groups. 
 
Study limitations 
This is a single-center, observational study with a fairly limited number of patients. 
Although at our institution all TAVI patients data are prospectively collected in a 
dedicate database and follow-up is continuously updated, classification of risk 
groups has been retrospective and clinical end points were self-adjudicated. 
Echocardiographic core laboratory was not available and, as in several 
retrospective studies on heart valve prostheses, the risk of underestimation of 
prosthesis dysfunction should be acknowledged. Another main limit of the study 
was the different follow-up duration among risk groups. In fact, the low risk group 
had a smaller number of patients at long-term follow-up when compared to the 
other ones, and this difference could have influenced the outcomes. 
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CONCLUSIONS 
 
In our study population including patients undergoing TAVI for AS or aortic bioprosthesis 
failure, TAVI was safe and effective, with low rates of mortality and adverse events 
regardless of the surgical risk. At longer follow-up mortality rate was significantly lower in 
low-risk patients. Pre-procedural CHF, neoplastic diseases, pre-procedural creatinine, post-
procedural severe bleedings and post-procedural AKI were predictors of late adverse events. 
THV performance after the procedure was excellent and stable over time with low rate of 
late prosthesis dysfunction. Further studies should be addressed to confirm the promising 
long-term results among low-risk patients and the long-term durability of THV.  
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